Beyond its metabolic effects, GLP1R is expressed in the central nervous system, where its activation influences satiety and may exert neuroprotective effects 11,12
The letters highlighted multiple safety concerns cited by the FDA, including dosing errors, substandard ingredients, and adverse health events
FDA labeling for weight management generally covers a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as prediabetes, hypertension, high cholesterol, or sleep apnea
Conclusions: Not applicable
Orforglipron offers the advantage of being a daily pill instead of a weekly injection
Recent developments in single-cell metabolomics by mass Spectrometry A perspective